德国CRISP注册研究:IIIB/C或IV期NSCLC可靶向基因变异检测的机构间差异
基于德国前瞻性真实世界CRISP注册研究(2016-2022年)6437例IIIB/C或IV期NSCLC患者,分析171家机构间可靶向基因变异(AGA)检测的差异。AGA检测率为77.9%,机构间预测概率从30.5%到93.2%不等,机构因素解释21.4%的总变异(p<0.001)。未进行AGA检测与更差生存独立相关(HRadj 1.11,95%CI 1.01-1.23,p=0.029)。
要点
- AGA检测率77.9%,机构间预测概率30.5%-93.2%,机构因素解释21.4%变异。
- 鳞癌亚组ICC 29.5%,KRAS检测ICC 34.4%,机构间差异更显著。
- 未检测AGA与更差生存独立相关(HRadj 1.11,95%CI 1.01-1.23)。
核心结论
- NSCLC的AGA检测存在显著机构间差异,且不能由患者或肿瘤特征解释。
- 未进行AGA检测与更差生存独立相关(HRadj 1.11,95%CI 1.01-1.23,p=0.029)。
研究设计与样本
- 前瞻性、观察性、多中心真实世界注册研究(CRISP,AIO-TRK-0315),纳入2016-2022年6437例IIIB/C或IV期NSCLC成人患者。
- 采用逻辑混合效应模型,以AGA检测为主要结局,纳入患者、肿瘤及治疗相关固定效应,机构为随机效应,覆盖171家机构。
主要发现
- AGA检测执行率为77.9%(n=5016)。
- 机构间AGA检测预测概率范围为30.5%至93.2%。
- 机构对检测使用有显著影响(p<0.001),解释21.4%的总变异。
- 机构间变异因机构类型显著不同,在鳞癌(ICC 29.5%)和KRAS检测(ICC 34.4%)亚组更明显。
- 未进行AGA检测与更差生存独立相关(HRadj 1.11,95%CI 1.01-1.23,p=0.029)。
临床怎么用
- 应关注不同机构间AGA检测实践模式的差异,推动检测标准化。
- 对鳞癌及KRAS检测等变异更明显的亚组,需加强检测规范。
- 未检测AGA与生存劣势相关,提示提高检测覆盖率可能改善患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular testing in NSCLC is essential for treatment selection, yet routine implementation remains inconsistent across institutions. Clinical evidence suggests that variability in testing may not be explained by patient or tumor characteristics but might be driven by institutional factors, potentially leading to adverse outcomes. We examined the extent to which variability in AGA testing is attributable to the treating institution. METHODS: We analyzed 6437 adults with stage IIIB/C or IV NSCLC enrolled in the prospective German real-world registry CRISP (2016-2022). Logistic mixed-effects models with AGA testing as the primary outcome were used to determine institutional variability across 171 institutions. Models included patient, tumor, and treatment-related fixed effects with institutions as random effects. Intraclass correlations (ICC) quantified institutional variability unexplained by other covariates. Institution type was tested in secondary analysis, and overall survival in exploratory analysis. FINDINGS: AGA testing was performed in 77.9 % of patients (n = 5016). Predicted probabilities for testing use ranged from 30.5 % to 93.2 % across institutions. Institutions significantly influenced testing use (p < 0.001), accounting for 21.4 % of the total variance. Variability significantly differed by institution type and was more pronounced in subgroups, e.g., squamous histology (ICC 29.5 %) and KRAS testing (ICC 34.4 %). Absence of AGA testing was independently associated with inferior survival (HRadj 1.11, 95 % CI 1.01-1.23, p = 0.029). INTERPRETATION: Substantial institutional variability exists in AGA testing for NSCLC, which was unexplained by patient or tumor characteristics. This objective evaluation of institution-based variability in testing may emphasize the importance of practice patterns on patient care and may therefore provide an avenue for change.
引用
- Althoff FC, Hummel HD, Kokowski K, et al. Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315). Eur J Cancer. 2026. PMID: 41633313. doi:10.1016/j.ejca.2026.116265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。